Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Perspective Therapeutics (CATX) Gross Margin (2016 - 2023)

Perspective Therapeutics' Gross Margin history spans 14 years, with the latest figure at 0.8% for Q4 2023.

  • On a quarterly basis, Gross Margin changed N/A to 0.8% in Q4 2023 year-over-year; TTM through Dec 2023 was 233.93%, a N/A change, with the full-year FY2023 number at 100.0%, changed N/A from a year prior.
  • Gross Margin hit 0.8% in Q4 2023 for Perspective Therapeutics, down from 33.78% in the prior quarter.
  • Over the last five years, Gross Margin for CATX hit a ceiling of 59.24% in Q1 2020 and a floor of 0.8% in Q4 2023.
  • Historically, Gross Margin has averaged 40.89% across 5 years, with a median of 45.69% in 2019.
  • Biggest five-year swings in Gross Margin: skyrocketed 1984bps in 2019 and later crashed -2291bps in 2023.
  • Tracing CATX's Gross Margin over 5 years: stood at 50.36% in 2019, then dropped by -2bps to 49.47% in 2020, then decreased by -12bps to 43.32% in 2021, then tumbled by -44bps to 24.11% in 2022, then crashed by -97bps to 0.8% in 2023.
  • Business Quant data shows Gross Margin for CATX at 0.8% in Q4 2023, 33.78% in Q3 2023, and 16.53% in Q2 2023.